Immuron Limited (NASDAQ: IMRN)
$2.62
-0.0600 ( -2.24% ) 1.8K
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Market Data
Open
$2.62
Previous close
$2.68
Volume
1.8K
Market cap
$14.36M
Day range
$2.58 - $2.68
52 week range
$1.48 - $5.96
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 5 | Apr 15, 2024 |
6-k | Quarterly Reports | 6 | Apr 10, 2024 |
6-k | Quarterly Reports | 27 | Mar 14, 2024 |
6-k | Quarterly Reports | 6 | Mar 07, 2024 |
6-k | Quarterly Reports | 7 | Mar 05, 2024 |
6-k | Quarterly Reports | 13 | Feb 28, 2024 |
6-k | Quarterly Reports | 36 | Feb 21, 2024 |
6-k | Quarterly Reports | 6 | Feb 13, 2024 |
6-k | Quarterly Reports | 17 | Feb 09, 2024 |
6-k | Quarterly Reports | 6 | Jan 16, 2024 |